Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1988-11-29
1992-12-29
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 11, 514179, 514252, 514282, 514289, 514327, A61K 3700, A61K 3156, A61K 21495, A61K 3150, A61K 3144, A61K 31445
Patent
active
051751445
ABSTRACT:
Progression of chronic renal failure can be retarded (slowed or arrested) by administering to humans suffering from such disorder an agent which suppresses the production of glucocorticoids in the human. The agents may be administered alone or in combination with a protein restricted and/or phosphorus restricted diet. Examples of suitable agents which either suppress production of glucocorticoids or block binding to their receptors include sodium valproate, enkephalins, opioids, clonidine, ketoconazole, oxytocin, and mifepristone.
REFERENCES:
patent: 3714159 (1973-01-01), Janssen et al.
patent: 4320146 (1982-03-01), Walser
The Merck Manual (14th edition, 1982) pp. 2388-2389.
Avery's Drug Treatment, 3rd edition (1987) pp. 897-898.
W. E. Mitch, et al., "The Effect of Keto Acid-Acid Supplement to Restricted Diet on the Progression of Chronic Renal Failure", The New England Journal of Medicine, 311:623-629 (Sep. 6), 1984.
J. Burns, et al., "Comparison of the effects of keto acid analogues and essential amino acids on nitrogen homeostasis in uremic patients on moderately protein-restricted diets", The American Journal of Clinical Nutrition 31: Oct. 1978, pp. 1767-1775.
M. Walser, et al., "Progression of chronic renal failure in patients given ketoacids following amino acids", Kidney International, vol. 32 (1987), pp. 123-128.
N. Gretz, et al., "Low-proteindiet supplemented by keto acids in chronic renal failure: A prospective controlled study", Kidney International, vol. 24, Suppl. 16 (1983), pp. S-263-S-267.
G. Barsotti, et al., "Effects on Renal Function of a Low-Nitrogen Diet Supplemented with Essential Amino Acids and Ketoanalogues and of Hemodialysis and Free Protein Supply in Patients with Chronic Renal Failure", Nephron 27:113-117 (1981).
T. Taylor, et al., "B-Endorphin Suppresses Adrenocorticotropin and Cortisol Levels in Normal Human Subjects", Journal of Clinical Endocripology and Metabolism, vol. 57, No. 3, pp. 592-596 (1983).
B. Ambrosi, et al., "Loperamide, an Opiate Analogue, Inhibits Plasma Acth Levels in Patients with Addison'Disease", Clinical endocrinology, 24, pp. 483-489 (1986).
G. Teutsch, et al., "17a-Alkynyl-11b,17-Dihydroxyandrostane Derivatives: A New Class of Potent Glucocortincoids.", Steroids, vol. 38, No. 6, pp. 651-665 (1981).
M. Moguilewsky, et al., "RU 38486: Potent Antiglucocorticoid Activity Correlated with Strong Binding to the Cytosolic Glucocorticoid Receptor Followed by an Impaired Activation", S. Steroid Biochem, vol. 20, No. 1, pp. 271-276 (1984).
Roland M. Schaefer, et al., "Evidence for Reduced Catabolism by the Antiglucocorticoid RU 38486 in Acutely Uremic Rats", Am. J. Nephrol, 7, pp. 127-131 (1987).
Xavier Bertagna, et al., "The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in Man", Journal of Clinical Endocrinology and Metabolism, vol. 59, No. 1, pp. 25-28 (1984).
J. J. Legros, et al., "Confirmation of the Inhibitory Influence of Exogenous Oxytocin on Cortisol and ACTH in Man: Evidence of Reproducibility", Acta Endocrinologica, 114: pp. 345-349 (1987).
Farwell, et al., "Total Suppression of Cortisol Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic Hormone Syndrome", The American Journal of Medicine, vol. 84 (Jun. 1988), pp. 1063-1066.
Stowinski-Srzednicka, et al., "Effect of Clonidine on Beta-Endorphin, ACTH and Cortisol Secretion in Essential Hypertension and Obesity," Eur. J. Clin. Pharmacol (1988) 35:115-121.
Lechin, et al., "Role of Stress in the Exacerbation of Chronic Illness: Effects of Clonidine Administration on Blood Pressure and Plasma Norepinephrine, Cortisol, Growth Hormone and Prolactin Concentrations,"Psychoneuroendocrinology, vol. 12, No. 2 pp. 117-129 (1987).
Stubbs, et al., "Hormonal and Metabolic Responses to an Enkephaline Analogue in Normal Man," The Lancet, Dec. 9, 1978, pp. 1225-1227.
Pende, et al., "Evaluation of the Effects Induced by Four Opiate Drugs, with Different Affinities to Opioid Receptor Subtypes, on Anterior Pituitary LH, TSH, PRL and GH Secretion and on Cortisol Secretion Normal Men,"Biomedicine & Pharmacotherapy, 1986, 40, 178-182.
Aggernaes, et al., "The Effect of Sodium Valproate on Serum Cortisol Levels in Healthy Subjects and Depressed Patients," Acta Psychiatr. Scand. 1988:77:170-174.
Nieman, et al. "Clinical Applications of the Glucocorticoid and Progestin Atnagonist RU 486," appearing in Receptor Mediated Antisteroid Action/Editor M. K. Agarwal (1987).
Gagne, et al., "RU38486: A Potent Antiglucocorticoid in Vitro and In Vivo," J. Steroid Biochem, vol. 23, No. 3, pp. 247-251 (1985).
Mitch et al., "Long-Term Effects of a New Ketoacid-Amino Acid Supplement in Patients with Chronoc Renal Failure," Kidney International, 22:48-53 (1982).
Henley III Raymond J.
The Johns Hopkins University
Waddell Frederick E.
LandOfFree
Method of retarding the progression of chronic renal failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of retarding the progression of chronic renal failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of retarding the progression of chronic renal failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1887103